Table 5.
Toxicities in the three largest multicenter studies with anti-CD19 CAR T-cell therapy for aggressive B-cell lymphomas.
| Study | ZUMA-1 (Locke, 2018) |
JULIET (Schuster)82 | TRANSCEND1 (Abramson et al.)87 |
|---|---|---|---|
| No patients enrolled (treated) | 111 (101) | 165 (111) | 134 (114) |
| Cytokine-release syndrome 2 | |||
| Time to onset, median, range | |||
| Duration, median, range | 2 days (1–12) | 3 days (1–9) | 5 days (2–12) |
| Grade (all) | |||
| Grade 3 or 4 | 8 days (NR) | 7 days (2–30) | 5 days (NR) |
| Tocilizumab use | 93% | 58% | 37% |
| Vasopressors use | 13% | 23% | 1% |
| Steroid treatment | 43% | 16% | 21% |
| ICU admission | 17% | 6% (high dose) | NR |
| 27% | 11% | 17% | |
| NR | NR | NR | |
| Infections | |||
| All grades | 35%3 | 34% | NR |
| Grade 3 or 4 | 31%3 | 20% | NR |
| Neurotoxicity 2 | |||
| Time to onset, median (range) | 5 days (1–17) | NR | 10 days (3–23) |
| Duration, median, range | 17 days (NR) | NR | 11 days (NR) |
| All grades | 64% | 20% | 23% |
| Grade 3 or 4 | 28% | 11% | 13% |
1
Reported from the full cohort data.
2
Grading was performed using the Penn criteria.
3
Febrile neutropenia.
ICU, intensive care unit; NR, not reported.